Robert W. Baird Forecasts Strong Price Appreciation for Castle Biosciences (NASDAQ:CSTL) Stock

Castle Biosciences (NASDAQ:CSTL) had its price objective raised by investment analysts at Robert W. Baird from $41.00 to $44.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Robert W. Baird’s price target indicates a potential upside of 48.80% from the company’s current price.

CSTL has been the subject of several other research reports. Zacks Research raised shares of Castle Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, February 2nd. Guggenheim boosted their price objective on shares of Castle Biosciences from $43.00 to $47.00 and gave the company a “buy” rating in a research report on Monday, January 26th. KeyCorp reaffirmed an “overweight” rating and issued a $50.00 target price on shares of Castle Biosciences in a research note on Thursday, January 29th. BTIG Research lifted their price target on Castle Biosciences from $38.00 to $50.00 and gave the company a “buy” rating in a research note on Friday, December 12th. Finally, Canaccord Genuity Group boosted their price target on Castle Biosciences from $37.00 to $50.00 and gave the company a “buy” rating in a report on Monday, December 22nd. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $47.57.

Castle Biosciences Stock Down 7.2%

Shares of Castle Biosciences stock opened at $29.57 on Friday. The company has a market capitalization of $863.15 million, a P/E ratio of -34.79 and a beta of 1.06. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.47 and a quick ratio of 6.31. The business has a 50-day moving average of $37.17 and a two-hundred day moving average of $31.21. Castle Biosciences has a 1 year low of $14.59 and a 1 year high of $44.28.

Castle Biosciences (NASDAQ:CSTL) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.15. Castle Biosciences had a negative return on equity of 0.89% and a negative net margin of 7.02%.The business had revenue of $81.88 million during the quarter, compared to analyst estimates of $81.19 million. As a group, equities analysts predict that Castle Biosciences will post 0.44 EPS for the current year.

Insider Transactions at Castle Biosciences

In related news, insider Derek J. Maetzold sold 4,017 shares of the stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $40.01, for a total transaction of $160,720.17. Following the completion of the transaction, the insider directly owned 87,715 shares of the company’s stock, valued at approximately $3,509,477.15. This represents a 4.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Kristen M. Oelschlager sold 14,888 shares of the firm’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $39.31, for a total value of $585,247.28. Following the completion of the transaction, the chief operating officer owned 12,323 shares of the company’s stock, valued at approximately $484,417.13. This represents a 54.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 29,617 shares of company stock valued at $1,167,887. Company insiders own 6.50% of the company’s stock.

Institutional Investors Weigh In On Castle Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in CSTL. Invesco Ltd. boosted its holdings in shares of Castle Biosciences by 142.6% in the 4th quarter. Invesco Ltd. now owns 135,461 shares of the company’s stock valued at $5,269,000 after buying an additional 79,621 shares during the last quarter. Mackenzie Financial Corp raised its position in Castle Biosciences by 54.2% during the fourth quarter. Mackenzie Financial Corp now owns 37,317 shares of the company’s stock worth $1,464,000 after acquiring an additional 13,113 shares in the last quarter. Empowered Funds LLC lifted its stake in Castle Biosciences by 24.2% in the fourth quarter. Empowered Funds LLC now owns 121,920 shares of the company’s stock valued at $4,743,000 after acquiring an additional 23,740 shares during the last quarter. XTX Topco Ltd bought a new position in shares of Castle Biosciences in the 4th quarter valued at about $861,000. Finally, Verdad Advisers LP bought a new position in shares of Castle Biosciences in the 4th quarter valued at about $276,000. Institutional investors own 92.60% of the company’s stock.

Key Castle Biosciences News

Here are the key news stories impacting Castle Biosciences this week:

• Positive Sentiment: Q4 / FY2025 results and 2026 revenue guide: Castle reported FY2025 revenue of $344M (above guidance) with Q4 revenues roughly in line with estimates and beat on EPS (Q4 GAAP EPS -$0.08 vs. consensus -$0.23). Management set 2026 revenue guidance of $340–$350M (slightly above the prior consensus ~$335M), supporting near‑term top‑line growth expectations. Castle Biosciences outlines 2026 revenue target
• Positive Sentiment: Product momentum and new launch: Core test reports (DecisionDx‑Melanoma and TissueCypher) rose ~37% in 2025 (TissueCypher +86%), and Castle launched AdvanceAD‑Tx (limited access), which expands the addressable market in atopic dermatitis. These operational wins support longer‑term growth potential. Earnings press release
• Positive Sentiment: Analyst upgrade / price target lift: Robert W. Baird raised its price target to $44 and reiterated an Outperform rating, signaling bullish analyst sentiment and implying notable upside from current levels. Baird raises target
• Neutral Sentiment: Additional coverage & materials: Earnings and investor materials (call transcript, slide deck) are available for deeper due diligence — useful for active investors reviewing guidance detail and management commentary. Press release & slide deck
• Neutral Sentiment: Street view: Recent coverage shows a generally constructive analyst stance (average “Moderate Buy” / multiple buy/outperform ratings), which can support sentiment if fundamentals hold. Analyst ratings roundup
• Negative Sentiment: Profitability and accounting headwinds: Despite revenue growth, Castle reported a GAAP net loss for 2025 of $24.2M (vs. net income in 2024) and adjusted EBITDA declined materially (from $75M to $44M). A one‑time acceleration of amortization (IDgenetix) and other items reduced margins — a drag on near‑term earnings power. Zacks earnings summary
• Negative Sentiment: Insider selling and discontinued tests: Public filings and summaries show heavy insider sales in recent months and the discontinuation of IDgenetix (lost volume), both of which can pressure sentiment and raise governance/operational questions for investors. Quiver / results summary

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.